Post
Spaulding Clinical Research, LLC Successful FDA Inspection
November 6, 2018
Press Release:
November 06, 2018 – Spaulding Clinical Research, LLC, a global clinical pharmacology, cardiac safety and biometrics solutions provider, announces the U.S. Food and Drug Administration (FDA) performed a routine inspection related to a specific clinical trial conducted in 2017. On the fifth and final day, the FDA auditor concluded that no observations or findings were identified and that all clinical trial results were well-organized and well-documented.
This is Spaulding Clinical’s first inspection for 2018 and this 5-Day FDA inspection is a great testament to the company’s investments in quality and talent.